Avid Bioservices Inc (CDMO)

[entdoc]

Today PPHM remains a very good bet. In fact, prospects have never appeared brighter for the company, and I have been invested and followed the company for many years. I would not hesitate to suggest Bavituximab to patients, family, and/or friends. From a clinician's point of view, I view those who have slowed its progress through the pipeline to be near-criminals. The price is a horrid disappointment to us all, and is an obvious reflection of the existence of more forces interested in keeping the price down than seeing it rise. The fact that well-known, acknowledged leaders in the field of immunology and MAB technology have never heard of PPHM or Bavi lends credence to the theory that widespread consumer AND professional acceptance is not merely a matter of promise, elapsed time, or efficacy. It takes a concerted effort by enormous PR forces to move the needle, and to date the financial community cannot endorse a starter with PPHM's track record when there are even many within the relevant scientific community who have never heard of it, and many who are taking a wait and see position. I have predicted for years that Bavi will pass muster with the FDA; that is not THE magic bullet for cancer; and that PPHM should go it alone for maximum stockholder gain. PPHM's Bavituximab has a very good safety profile; low side-effects, and established anti-tumor activity. Bavi-, or Bavi-like medications will eventually be used in conjunction with a vast array of medications, and as a nasal spray prophylaxis in combination with antibiotics. PPHM's anti-PS platform is solid, and will grow exponentially once it can market its first spin-off. Cheers to all present on the "long march", and recent converts.